Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy

被引：35
作者：
McGowan T.A. [1 ]
Zhu Y. [1 ]
Sharma K. [1 ]
机构：
[1] Dorrance Hamilton Res. Laboratories, Division of Nephrology, Thomas Jefferson University Hospital, Philadelphia, PA 19107
来源：
Current Diabetes Reports | 2004年 / 4卷 / 6期
基金：
美国国家卫生研究院;
关键词：
Diabetic Nephropathy; Idiopathic Pulmonary Fibrosis; Mesangial Cell; Renal Fibrosis; Diabetic Kidney Disease;
D O I：
10.1007/s11892-004-0055-z
中图分类号：
学科分类号：
摘要：
Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming grcmdh factor-β (TGF-β) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-β on matrix accumulation but have also found that blocking TGF-β may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-β in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：447 / 454
页数：7
相关论文
共 75 条
[31]  
Houlihan C., Akdeniz A., Tsalamandris C., Et al., Urinary transforming growth factor-beta enartion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: Effects of angiotensin receptor blockade and sodium restriction, Diabetes Care, 25, pp. 1072-1077, (2002)
[32]  
Sharma K., Eltayeb B., McGowan T., Et al., Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients, Am. J. Kidney Dis., 34, pp. 818-823, (1999)
[33]  
Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy, N. Engl. J. Med., 329, pp. 1456-1462, (1993)
[34]  
Campistol J., Inigo P., Jimenez W., Et al., Losartan decreases plasma levels of TGF-beta 1 in transplant patients with chronic allograft nephropathy, Kidney Int., 56, pp. 714-719, (1999)
[35]  
Agarwal R., Siva S., Dunn S.R., Sharma K., Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-(beta) levels, Am. J. Kidney Dis., 39, pp. 486-492, (2002)
[36]  
Brenner B., Cooper M., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N. Engl. J. Med., 345, pp. 861-869, (2001)
[37]  
Riser B., Cortes P., Heilig C., Et al., Cyclic stretching forces selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells, Am. J. Pathol., 148, pp. 1915-1923, (1996)
[38]  
Jafar T., Stark P., Schmid C., Et al., Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, Ann. Intern. Med., 139, pp. 244-252, (2003)
[39]  
Sharma K., Ziyadeh F.N., Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse, Am. J. Physiol., 267, (1994)
[40]  
Park I.S., Kiyomoto H., Abboud S., Abboud H., Expression of transforming growth factor-beta and type IV coHagen in early streptozotocin-induced diabetes, Diabetes, 46, pp. 473-480, (1997)
12345678